Kevin Patrick Danahy - Oct 23, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Executive Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Oct 23, 2023
Transactions value $
$0
Form type
4
Date filed
11/3/2023, 05:41 PM
Previous filing
Jul 14, 2023
Next filing
Nov 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award $0 +130K $0.00 130K Oct 23, 2023 Common Stock 130K $3.96 Direct F1
transaction PLSE Stock Option (right to buy) Other $0 -130K -100% $0.00* 0 Nov 1, 2023 Common Stock 130K $3.96 Direct F1, F2
transaction PLSE Stock Option (right to buy) Award $0 +460K $0.00 460K Nov 1, 2023 Common Stock 460K $4.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
F2 Reporting Person was erroneously granted an option to acquire 130,000 shares on October 23, 2023, which option was cancelled by mutual agreement on November 1, 2023.
F3 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.